# Azole-echinocandin Combination Therapy for Invasive Aspergillosis

> **NCT04876716** · PHASE3 · TERMINATED · sponsor: **Erasmus Medical Center** · enrollment: 66 (actual)

## Conditions studied

- Invasive Aspergillosis

## Interventions

- **DRUG:** Azole
- **DRUG:** Anidulafungin

## Key facts

- **NCT ID:** NCT04876716
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-11
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** futility
- **Last updated:** 2024-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876716, "Azole-echinocandin Combination Therapy for Invasive Aspergillosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04876716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*